Category: atopic dermatitis

According to a recent study, lebrikizumab, a monoclonal antibody targeting IL-13, is effective in treating head and neck atopic dermatitis (AD) and erythema at 16 weeks of treatment.

According to a recent study, patients with more severe chronic hand eczema were willing to dedicate a substantial amount of time daily for treatment. 

In a recent study, researchers have identified specific risk factors for anxiety and depression in atopic dermatitis (AD) patients, including a lower education level and severe pruritus.

According to a recent study, ivarmacitinib, a Januse kinase (JAK)-1 inhibitor, has been shown to be effective and safe in treating adolescent and adult patients with atopic dermatitis (AD).

According to a recent study, patients with moderate-to-severe atopic dermatitis (AD) experience significant disease burden with physical, emotional, and social impact.

Dr. Christine Neagoe and Dr. Mohannad Abu-Hilal from Hamilton, Ontario, recently discussed the management of atopic dermatitis (AD) through topical and systemic treatments on the Skin Spectrum Podcast.

According to a recent study, upadacitinib is efficacious and demonstrated a favorable benefit-risk profile for long-term treatment of atopic dermatitis (AD) in adolescent patients.

According to a recent study, a combination of dupilumab and abrocitinib is effective in treating refractory atopic dermatitis (AD) in pediatric patients.

According to a recent study, risk of pediatric atopic dermatitis (AD) is associated with childhood obesity and correlated to weight loss and gain.

According to a recent study, cendakimab is safe and efficacious in treating moderate-to-severe atopic dermatitis (AD) in adult patients.